Transcription Factor IRF7 is Involved in Psoriasis Development and Response to Guselkumab Treatment
Xiuqing Yuan,Tiantian Xin,Huanhuan Yu,Jian Huang,Yaohan Xu,Caixin Ou,Yongfeng Chen
DOI: https://doi.org/10.2147/jir.s450048
IF: 4.5
2024-02-15
Journal of Inflammation Research
Abstract:Xiuqing Yuan, 1, &ast Tiantian Xin, 1, &ast Huanhuan Yu, 1 Jian Huang, 2 Yaohan Xu, 1 Caixin Ou, 1 Yongfeng Chen 1 1 Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong Province, People's Republic of China; 2 Department of Dermatology, Guangdong College of Clinical Dermatology, Anhui Medical University, Hefei, Anhui Province, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yongfeng Chen, Dermatology Hospital of Southern Medical University, No. 2, LuJing Road, Guangzhou, Guangdong Province, 510091, People's Republic of China, Tel +86 13802920269, Email Purpose: Guselkumab is a highly effective biologic agent for treating psoriasis. This study aimed to explore potential transcription factors involved in psoriasis pathogenesis and response to guselkumab treatment, aiming to provide new therapeutic strategies for psoriasis. Patients and Methods: We analyzed gene expression and single-cell RNA-seq data from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) that upregulated in psoriasis and downregulated after guselkumab treatment were subjected to enrichment analyses. Single-cell regulatory network inference and clustering (SENIC) and regulon module analyses identified different regulon activities between the lesion and non-lesion skin of psoriasis. Cell-cell communication analysis revealed interactions among specific cell clusters. Transcription factor (TF) regulons were identified from the guselkumab-specific regulon network. Gene set enrichment analysis (GSEA) confirmed the IRF7 regulon in the validation cohort. Finally, the expression level of IRF7 was identified in plaque psoriasis before and after 12 weeks of guselkumab therapy by immunohistochemical experiment. Results: 799 DEGs were downregulated after guselkumab treatment. Enrichment analyses highlighted the interleukin-17 (IL-17) pathway in this gene set. The M2 module exhibited the primary difference in regulon activity. Strong cell-cell interactions were observed between keratinocytes and immune cells. IRF7 regulon had significant roles in psoriasis and treatment response, as validated by GSEA analysis using the IL-17 signaling pathway as a reference. The immunohistochemical analysis unveiled substantial differences in the expression levels of IRF7 in psoriatic skin samples before and after 12 weeks of guselkumab treatment. Conclusion: IRF7 may be the key player in psoriasis pathogenesis and the therapeutic process involving guselkumab. Targeting IRF7 might offer new therapeutic strategies for psoriasis. Keywords: guselkumab, plaque psoriasis, IL-23/IL-17 signaling pathway, SENIC analysis, TF regulon Psoriasis is a chronic skin disorder distinguished by the appearance of red plaques and scaly patches arising from aberrant keratinocyte differentiation and excessive proliferation. 1 It impacts an estimated global population of 125 million individuals, leading to substantial declines in both quality of life and economic burdens. 2 This complex disease is influenced by immunological, genetic, and environmental factors, leading to the development of various treatment and management strategies targeting its underlying causes. 3,4 Since the interleukin-23/ interleukin-17 (IL-23/IL-17) signaling pathway plays a pivotal role in its pathogenesis, 5,6 monoclonal antibodies targeting this pathway have been developed and approved for clinical use, marking a paradigm shift in psoriasis management. 7,8 Guselkumab, an IL-23-specific antibody, has demonstrated high efficacy in treating psoriasis. 9 Although guselkumab primarily acts through the IL-23/IL-17 axis, the potential underlying mechanisms have not yet been fully explored. An in-depth exploration of guselkumab therapy from multiple perspectives could provide a comprehensive understanding of the IL-23/IL-17 pathway and help identify effective therapeutic targets for psoriasis. Transcription factors (TFs) play a pivotal role in controlling gene expression, exerting their influence over a wide array of biological processes, including metabolism, immune response, organ development, and cellular differentiation. 10 Dysregulation of TF activity can contribute to diseases like cancer, diabetes, and autoimmune disorders. 11–13 Targeting TFs with drugs holds promise for therapeutically modulating gene expression, including in psoriasis treatment. The IL-23/IL-17 pathway is currently being investigated to identify potential therapeutic targets. For instance, targeting RORγT, a key regulator of Th17 ce -Abstract Truncated-
immunology